Carbazochrome salicylate

Erythromycylamine is a semi-synthetic analogue of erythromycin prepared by reduction of erythromycin oxime. Erythromycyclamine is a potent antibiotic, however the introduction of the amino- moiety increases the compound's polarity and is

Erythromycylamine is a semi-synthetic analogue of erythromycin prepared by reduction of erythromycin oxime. Erythromycyclamine is a potent antibiotic, however the introduction of the amino- moiety increases the compound's polarity and is

Erythromycylamine is a semi-synthetic analogue of erythromycin prepared by reduction of erythromycin oxime. Erythromycyclamine is a potent antibiotic, however the introduction of the amino- moiety increases the compound's polarity and is

HABA

A cell-permeable benzoxadiazolamine that prevents HIF-2&#945-HIF-&#946/ARNT heterodimeration by perturbing HIF-2&#945 Per-ARNT-Sim/PAS-B domain surface &#946-sheet conformation via a 1:1 stoichiometric binding ( K D = 81 nM), while exhibiting

A cell-permeable benzimidazolopyrazole compound that acts as an active-site binding, iron insensitive, 2-oxoglutarate competitive, reversible and potent inhibitor of PHD1, 2 and 3 isozymes (pK i = 7.91, 7.

HQL-79 is a selective inhibitor of hematopoietic PGD synthase. Structurally, it is a synthetic tetrazole compound originally prepared as a possible antihistamine.

HQL-79 is a selective inhibitor of hematopoietic PGD synthase. Structurally, it is a synthetic tetrazole compound originally prepared as a possible antihistamine.

HQL-79 is a selective inhibitor of hematopoietic PGD synthase. Structurally, it is a synthetic tetrazole compound originally prepared as a possible antihistamine.

HQL-79 is a selective inhibitor of hematopoietic PGD synthase. Structurally, it is a synthetic tetrazole compound originally prepared as a possible antihistamine.

Isobutyl Salicylate.

Isobutyl Salicylate.